Contact us Find us Register
Back to previous section

Final results for the year ended 31 December 2024.

    30 April 2025 11:18:56
  • Source: Sharecast
RNS Number : 8506G
Cizzle Biotechnology Holdings PLC
30 April 2025
 

30 April 2025

Cizzle Biotechnology Holdings plc

 

("Cizzle", "Cizzle Biotechnology", or the "Company")

 

Final results for the year ended 31 December 2024

 

Cizzle Biotechnology, the UK based diagnostics developer of early cancer tests, announces the publication of the Company's Annual Report and Financial Statements for the year ended 31 December 2024 ("Annual Report").

The Annual Report is available via http://www.rns-pdf.londonstockexchange.com/rns/8506G_1-2025-4-30.pdf and will shortly be available to view on the on the National Storage Mechanism (NSM) and the Company's website: https://cizzlebiotechnology.com

Enquiries:

 

Cizzle Biotechnology Holdings plc

Via IFC Advisory

Allan Syms (Executive Chairman)


 

Allenby Capital Limited

+44(0) 20 3328 5656

John Depasquale / Piers Shimwell (Corporate Finance)


Stefano Aquilino / Amrit Nahal (Sales and Corporate Broking)


 

IFC Advisory Limited

+44(0) 20 3934 6630

Tim Metcalfe


Florence Staton





 

About Cizzle Biotechnology

Based on the pioneering work of Professor Coverley and colleagues, on a naturally occurring variant of the cell nuclear protein CIZ1, the CIZ1B biomarker is highly associated with the presence of early-stage cancer. The company has developed CIZ1B into a non-invasive, cost-effective blood test to help in the early detection of lung cancer and has now entered into commercial royalty-bearing arrangements to license its proprietary technology, and into collaborations with centres of excellence in cancer care.  Cizzle was admitted to the Standard segment of the main market of the London Stock Exchange in May 2021. 

 

For more information, please see https://cizzlebiotechnology.com

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACSEAELEDFKSEFA

Compare our accounts

If you're looking to grow your money over the longer term (5+ years), we have a range of investment choices to help.

View our accounts

Halifax is not responsible for the content and accuracy of the Markets News articles. We may not share the views of the author. Understand the risks, please remember the value of your investment can go down as well as up and you may not get back the full amount you invest. We don't provide advice so if you are in any doubt about buying and selling shares or making your own investment decisions we recommend you seek advice from a suitably qualified Financial Advisor. Past performance is not a guide to future performance.